Nothing Special   »   [go: up one dir, main page]

CO6420342A2 - Derivados de pirazol usados como antagonistas del receptor ccr4 - Google Patents

Derivados de pirazol usados como antagonistas del receptor ccr4

Info

Publication number
CO6420342A2
CO6420342A2 CO11109505A CO11109505A CO6420342A2 CO 6420342 A2 CO6420342 A2 CO 6420342A2 CO 11109505 A CO11109505 A CO 11109505A CO 11109505 A CO11109505 A CO 11109505A CO 6420342 A2 CO6420342 A2 CO 6420342A2
Authority
CO
Colombia
Prior art keywords
ccr4
recruitor
receiver
derivatives used
pirazol derivatives
Prior art date
Application number
CO11109505A
Other languages
English (en)
Inventor
Heather Hobbs
Simon Teanby Hodgson
Yannick Maurice Lacroix
Deborah Needham
Nigel James Parr
Panayiotis Alexandrou Procopiou
Timoty John Ritchie
Michael David Woodrow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6420342A2 publication Critical patent/CO6420342A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de indazol (I), procedimientos para su preparación, intermedios útiles en estos procedimientos, composiciones farmacéuticas que contienen dichos compuestos y su uso en terapia relacionada a antagonistas del receptor CCR4.
CO11109505A 2009-02-26 2011-08-26 Derivados de pirazol usados como antagonistas del receptor ccr4 CO6420342A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15570209P 2009-02-26 2009-02-26

Publications (1)

Publication Number Publication Date
CO6420342A2 true CO6420342A2 (es) 2012-04-16

Family

ID=42110309

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11109505A CO6420342A2 (es) 2009-02-26 2011-08-26 Derivados de pirazol usados como antagonistas del receptor ccr4

Country Status (31)

Country Link
US (3) US8304446B2 (es)
EP (1) EP2401270B1 (es)
JP (1) JP5520969B2 (es)
KR (1) KR20110128896A (es)
CN (1) CN102388039B (es)
AR (1) AR075594A1 (es)
AU (2) AU2010217629A1 (es)
BR (1) BRPI1013396A2 (es)
CA (1) CA2753337A1 (es)
CL (1) CL2011002103A1 (es)
CO (1) CO6420342A2 (es)
DK (1) DK2401270T3 (es)
DO (1) DOP2011000272A (es)
EA (1) EA021740B1 (es)
ES (1) ES2439773T3 (es)
HK (1) HK1159621A1 (es)
HR (1) HRP20131174T1 (es)
IL (1) IL214655A0 (es)
MA (1) MA33132B1 (es)
MX (1) MX2011008972A (es)
NZ (1) NZ594641A (es)
PE (1) PE20120307A1 (es)
PL (1) PL2401270T3 (es)
PT (1) PT2401270E (es)
RS (1) RS53133B (es)
SG (1) SG173768A1 (es)
SI (1) SI2401270T1 (es)
SM (1) SMT201400001B (es)
TW (1) TW201041879A (es)
UY (1) UY32464A (es)
WO (1) WO2010097395A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009028588A1 (ja) 2007-08-31 2009-03-05 Eisai R & D Management Co., Ltd. 多環式化合物
CN102333778B (zh) 2009-02-26 2015-05-13 卫材R&D管理有限公司 四氢三唑并吡啶衍生物的盐及其晶体
NZ594776A (en) 2009-02-26 2013-05-31 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
US8729260B2 (en) * 2010-05-19 2014-05-20 Savior Lifetec Corporation Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem
WO2012025473A1 (en) * 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
CN111349087B (zh) * 2014-02-20 2023-07-14 康奈尔大学 用于抑制肌成束蛋白的化合物和方法
JP6985388B2 (ja) * 2016-07-29 2021-12-22 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びそれの使用
WO2018049271A1 (en) 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
WO2018187509A1 (en) 2017-04-04 2018-10-11 Flx Bio, Inc. Heterocyclic compounds as chemokine receptor modulators
CA3056501A1 (en) * 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
CA3081750A1 (en) 2017-11-06 2019-05-09 Rapt Therapeutics, Inc. Anticancer agents
CN110028501B (zh) 2018-01-12 2022-02-22 迈德欣国际有限公司 化合物及其制备方法和用途
AU2019212478C1 (en) 2018-01-26 2023-11-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
CN113893220A (zh) * 2020-07-07 2022-01-07 迈德欣国际有限公司 鼻粘膜给药剂型和其应用
US20230322741A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
KR20050084271A (ko) * 2002-12-12 2005-08-26 아방티 파르마 소시에테 아노님 아미노인다졸 유도체 및 키나제 억제제로서의 이의 용도
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer

Also Published As

Publication number Publication date
HRP20131174T1 (hr) 2014-01-17
US20100216860A1 (en) 2010-08-26
US8357716B2 (en) 2013-01-22
US20120015932A1 (en) 2012-01-19
PT2401270E (pt) 2014-01-20
EA021740B1 (ru) 2015-08-31
EA201190142A1 (ru) 2012-05-30
US8304446B2 (en) 2012-11-06
WO2010097395A1 (en) 2010-09-02
SMT201400001B (it) 2014-03-07
PE20120307A1 (es) 2012-04-04
MA33132B1 (fr) 2012-03-01
AU2016203684A1 (en) 2016-06-23
CL2011002103A1 (es) 2012-02-24
AR075594A1 (es) 2011-04-20
SG173768A1 (en) 2011-09-29
CN102388039A (zh) 2012-03-21
EP2401270B1 (en) 2013-10-16
TW201041879A (en) 2010-12-01
KR20110128896A (ko) 2011-11-30
CA2753337A1 (en) 2010-09-02
EP2401270A1 (en) 2012-01-04
AU2010217629A1 (en) 2011-09-15
US20130030031A1 (en) 2013-01-31
NZ594641A (en) 2013-03-28
SI2401270T1 (sl) 2014-01-31
BRPI1013396A2 (pt) 2016-03-29
HK1159621A1 (en) 2012-08-03
US8507543B2 (en) 2013-08-13
CN102388039B (zh) 2015-07-15
IL214655A0 (en) 2011-09-27
ES2439773T3 (es) 2014-01-24
JP2012518673A (ja) 2012-08-16
RS53133B (en) 2014-06-30
PL2401270T3 (pl) 2014-03-31
DOP2011000272A (es) 2011-12-31
DK2401270T3 (da) 2014-01-13
MX2011008972A (es) 2011-12-14
UY32464A (es) 2010-09-30
JP5520969B2 (ja) 2014-06-11

Similar Documents

Publication Publication Date Title
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
ECSP12012042A (es) Derivados de pirazol como inhibidores de jak
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
CR11802A (es) Derivados de indazoles sustituidos con fenilo o piridinilo
PA8638801A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CO6541643A2 (es) Derivados de imidazopirina como inhibidores de jak
UY32239A (es) Nuevos derivados de (3-oxo)piridazin-4-ilurea
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
CL2008001815A1 (es) Compuestos derivados de indazol; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
BR112015012720A2 (pt) derivados de feniletilpiridina como inibidores de pde4
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
NI201000089A (es) Derivados de pirazol como inhibidores de 5-lo.
ES2418032R1 (es) Derivados de 2-(1-fenil-4,5,6,7-tetrahidro-1h-indazol-4-il)etilamina utiles como inhibidores de receptores sigma
CU23564A3 (es) Derivados de carboxamida como antagonistas del receptor muscarínico

Legal Events

Date Code Title Description
FG Application granted